期刊
NPJ BREAST CANCER
卷 7, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41523-021-00223-x
关键词
-
类别
资金
- GlaxoSmithKline
- Istituto Oncologico Veneto project [L02P38]
- University of Padova [60A07-7808/13]
- Istituto Oncologico Veneto projects [L04P11, L02P03, L04P25, L03P07, L05P07]
- University of Padova-Department of Surgery, Oncology and Gastroenterology
The study revealed differences in immune infiltration between hormone receptor positive and HER2 negative breast cancer subtypes, with non-luminal tumors showing higher levels of tumor-infiltrating lymphocytes and a more proinflammatory antitumor immune infiltrate composition compared to luminal tumors.
Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据